News

July 07, 2020

Health Canada Authorizes Precision Biomonitoring to Import and Sell Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test in Response to COVID-19

Ultra-portable testing solution approved for use across Canada

GUELPH, ON and PHILADELPHIA, July 7, 2020 /CNW/ – Biomeme and Precision Biomonitoring, industry leaders in rapid DNA field detection, announce that Health Canada has approved Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test and rapid mobile detection platform for immediate deployment across Canada by Precision Biomonitoring. Approval was based on lab validation data generated through stringent testing of viral samples in performance areas including sensitivity and specificity. The approval is aligned with the Government of Canada’s ongoing commitment to collaborate with innovative companies dedicating their efforts to combating the pandemic.

“This approval is the result of the dedication and commitment of our teams at Precision Biomonitoring and Biomeme, as well as ongoing collaboration with our validation partners,” says Dr. Mario Thomas, CEO of Precision Biomonitoring. “This rapid test can now be distributed everywhere across Canada, especially in remote areas and workplaces where creating virus-free zones is vital. We can now bring the lab to the sample.”

More About the Biomeme Device & Software

Weighing only 1.2 kg, battery-operated and able to deliver results for up to nine samples in about 60 minutes, the mobile device and its easy-to-use software are ideal for all locations where screening is needed such as assessment centers, long-term care and nursing homes, retirement communities, ships, airports, borders and more distant regions. Precision Biomonitoring has also partnered with Guelph-based environmental consulting firm, Shared Value Solutions, to bring the approved rapid mobile testing platform to Indigenous communities in northern Ontario in response to COVID-19.

A free and intuitive smartphone mobile app pairs wirelessly with the device to easily run, monitor, and analyze the results of each test. Tests can be run online or offline, results can be interpreted in real-time, and all data can be securely synced to the cloud. Both the device and smartphone can be transported in a laptop-sized bag making it ideal for spot tests, especially when results are now needed in emergency rooms and more rural and remote regions.

More About the Test

The SARS-CoV-2 Real-Time RT-PCR Test requires no special lab equipment or cold chain and is intended for the qualitative detection of RNA from SARS-CoV-2 in nasopharyngeal and oropharyngeal (throat) swab samples. The assay’s two RNA targets are multiplexed together with Biomeme’s RNA extraction and RT-PCR process control in a single triple reaction. While being able to perform these tests in remote areas and workplaces is critical, the SARS-COV-2 test is also being manufactured in form factors suitable for high throughput labs. Here is a summary of each shelf-stable, pre-mixed form factor approved for use by health care providers across Canada:

  • 3-Well Go-StripsTM: Optimized for performance in the field. Each Go-StripTM has 3 reaction wells and each well contains a 20 µL lyophilized triplex reaction. With this form factor, there is no aliquoting or mixing of components in the field. You just add your sample to the strips and begin your test.
  • 96-Well Go-PlatesTM: Optimized for high throughput lab use in standard commercial thermocyclers (Bio-Rad CFX96, ABI QuantStudio5). Just like above, each Go-PlateTM is shelf-stable, pre-mixed, and pre-aliquoted with the same lyophilized triplex reaction.
  • Bulk Vials: Optimized more for lab use in any thermocycler. Each vial is shelf-stable, pre-mixed and lyophilized, but they are not pre-aliquoted, so you are free to use your own plastics.

“Having a reliable rapid test is critical for controlling the spread of COVID-19, especially in certain communities or rural settings where testing may take longer. It will allow these communities to get results faster and will enable healthcare professionals to take the necessary steps to expedite their response to COVID-19 cases,” said Dr. Rob Kozak, clinical microbiologist at Sunnybrook Health Sciences Centre.

The approval from Health Canada, combined with these capabilities and various form factors, allows Precision Biomonitoring to contribute to initiatives and programs recently implemented by the Government of Canada, as well as close to home in Ontario, where the government continues to focus on increasing testing capacity and creating safe workplaces.

To learn more about the different COVID-19 testing kits available, please visit pbidiagnostic.com

Third Party Clinical Evaluations

Northwell Health is New York State’s largest healthcare employer, with more than 68,000 employees and home to 23 hospitals and more than 700 outpatient facilities, as well as urgent care centers, kidney dialysis centers, acute inpatient rehabilitation, sub-acute rehabilitation and skilled-nursing facilities, a home care network, a hospice network, and other services. Northwell completed a clinical evaluation of the Biomeme SARS-CoV-2 Real-Time RT-PCR Test with clinical nasopharyngeal and oropharyngeal samples with a range of Ct values. This evaluation utilized 65 samples tested with 4 comparator platforms: GenMark ePlex, Hologic Panther Fusion, Wadsworth/CDC and Roche Cobas 8800. It found a 98% correlation (64/65).

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

About Biomeme

Biomeme entered into molecular detection over 7 years ago when it created the first iPhone add-on capable of performing real-time PCR. Since its inception, Biomeme has used advanced biology and chemistry, along with world-class hardware and software engineering, to create elegant solutions to complex problems. Headquartered in Philadelphia, USA, Biomeme offers a full suite of end-to-end mobile molecular solutions. Biomeme’s 1-minute sample prep, shelf-stable reagents, hand-held thermocycler, cloud portal, and web API perform to the gold standard used by the world’s most advanced central labs but require no lab equipment or special experience to use.

SOURCE Precision Biomonitoring

For further information: Media Contact: Meredith Adams, 416-459-7086, Madams@national.ca

July 7, 2020

Precision Biomonitoring Announces Appointment of Dr. Eric Hoskins to Board of Directors

Dr. Hoskins Brings Expertise to Precision Biomonitoring’s Innovative Efforts in Health

GUELPH, ON and MISSISSAUGA, ON, July 7, 2020 /CNW/ – Precision Biomonitoring, an industry leader in offering point-of-need molecular detection tools for rapid results on the spot, is pleased to announce that Dr. Eric Hoskins, former Minister of Health of Ontario, has joined Precision Biomonitoring’s Board of Directors.

“We are looking forward to working closely with Dr. Hoskins,” says Dr. Mark Goldberg, Chair, Precision Biomonitoring board of directors. “His established leadership and experience in Canadian healthcare will be an asset and complement to the existing expertise we have at Precision Biomonitoring, especially as we continue our focus on the health of Canadians through our efforts in response to COVID-19.”

Dr. Hoskins has over thirty years’ experience as a physician and public health specialist. Most recently, Dr. Hoskins was Chair of the Federal Advisory Council on the Implementation of National Pharmacare.

Dr. Hoskins’ political experience will also bring valuable insights to Precision Biomonitoring as it continues to work closely with partners in government, health and technology innovation. Throughout his nearly ten years in provincial politics, Dr. Hoskins held critical roles, including as Ontario’s Minister of Health and Long-Term Care (2014-2018) where he was responsible for one of the largest healthcare systems in North America.

“Precision Biomonitoring is passionate about creating innovative Canadian solutions that serve and protect the health of Canadian and global citizens,” says Dr. Hoskins. “Their vision is closely aligned with my own and I am excited to join their Board as they make important advancements in the healthcare space.”

Additional members of Precision Biomonitoring’s Board of Directors include Dr. Mario Thomas, Co-founder and CEO, Precision Biomonitoring; Dr. Mark Goldberg, Co-founder, Plantform Inc.; John Ferraro, Chairman, JS Ferraro & Co.; John Pearson, President, QDZ Enterprises Ltd.

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

SOURCE Precision Biomonitoring

For further information: Media Contact: Meredith Adams, 416-459-7086, Madams@national.ca

April 10, 2020

Collaboration to Provide Rapid SARS-CoV-2 Go-Strips to Communities in Northern Ontario

GUELPH, ON and MISSISSAUGA, ON, April 9, 2020 /CNW/ – Precision Biomonitoring, an industry leader in offering point-of-need molecular detection tools for rapid results on the spot, has announced its partnership with Guelph-based environmental consulting firm, Shared Value Solutions, to bring its point-of-need SARS-CoV-2 Go-Strips and rapid mobile detection device to Indigenous communities in northern Ontario, in response to COVID-19.

“We are all in this together,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “For Canada to be successful in both flattening the curve and eventually combatting the virus, we need to ensure that all Canadians are receiving access to necessary tools, especially communities who are most vulnerable. Our rapid point-of-need solution is designed to do just that.”

At present, the delivery of COVID-19 test results can take up to seven days in northern road-connected communities and can take even longer in more remote communities. With the ability to administer nine tests per hour at the point-of-need and deliver results in about 60 minutes, the 1.2 kg battery-operated, mobile COVID-19 test solution will help to increase testing speed and capacity.

Precision Biomonitoring’s SARS-CoV-2 Go-Strips are currently awaiting expedited approval from Health Canada. Shared Value Solutions is hopeful that it will be able to provide this testing technology to northern Indigenous communities in Ontario and across Canada in the near future, immediately following Health Canada approval.

The collaborative efforts of Precision Biomonitoring and Shared Value Solutions will help to address the growing number of cases in First Nations and Inuit communities, as recently confirmed by Indigenous Services Canada (ISC), while also supporting the federal government’s commitment to the well-being of these vulnerable populations, as made evident by the new distinctions-based Indigenous Community Support Fund to address immediate needs related to COVID-19.

“From creating a hand sanitizer supply chain for the north to offering free support to First Nations departments operating with limited capacity, we are doing everything we possibly can to support our clients’ greatest needs during this crisis. This new rapid testing option fills a crucial part of that need,” says Scott Mackay, CEO, Shared Value Solutions. “To be able to provide support alongside the dedicated team at Precision Biomonitoring, who already shares an interest in issues important to Indigenous communities, including environmental protection, makes us truly confident that this collaboration will provide the innovative care and testing desperately needed in these communities.”

About Precision Biomonitoring 
Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

About Shared Value Solutions
Shared Value Solutions (SVS) is an environmental and community development consulting firm based in Ontario with employees also based in British Columbia, Alberta and New Brunswick. Our team works for and with Indigenous nations across Canada, providing technical guidance, regulatory advice, environmental peer reviews, negotiation and business strategy, and various supporting studies in relation to resource and infrastructure projects in our clients’ territories. Our company is made up of an interdisciplinary group of environmental scientists, planners, anthropologists and social researchers, and community engagement practitioners with a wide range of experience working for Indigenous communities, tribal councils and governments across the country. At the core of SVS’s work is the integration of environmental, social, cultural, economic values, advocacy for community health and well-being, and the protection of the environment and Indigenous rights.

SOURCE Precision Biomonitoring

For further information: Media Contact: Meredith Adams, 416-459-7086, Madams@national.ca

March 31, 2020

Precision Biomonitoring Receives Letter of Intent from the Government of Canada for its Testing Capabilities in Response to COVID-19

Point-of-need COVID-19 test awaiting approval by Health Canada 

GUELPH, Ontario and MISSISSAUGA, Ontario, March 31, 2020 – Precision Biomonitoring, an industry leader in developing environmental DNA (eDNA) tools to detect organisms at the point-of-need in 60 minutes, announces that it has been selected by the Government of Canada through a Letter of Intent with Public Services and Procurement Canada (PSPC) and Innovation, Science and Economic Development Canada (ISED) for its point-of-need SARS-CoV-2 Go-Strips test and battery-operated instrument in response to COVID-19. Precision Biomonitoring is one of the first ten companies to receive a Letter of Intent in the COVID-19 procurement space.

SARS-CoV-2 Go-Strips detect the RNA of severe acute respiratory syndrome, COVID-19. The COVID-19 RNA targets are multiplexed together with Biomeme’s RNA positive control, which is an RNA extraction and RT-PCR control, allowing results to be obtained onsite in 60 minutes. Early identification and diagnosis of COVID-19 is crucial to ensure a rapid response, thus mitigating the possible additional negative consequences of the virus. Weighing only 1.2 kg and battery-operated, Precision Biomonitoring’s mobile solution is ideal for all point-of-need locations where screening is needed for vulnerable populations such as assessment centers, long-term care homes, ships, airports, borders and more distant regions and remote areas. The test is currently awaiting Health Canada approval.

“We are immensely proud to have been selected as an early partner by our Federal Government,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “Precision Biomonitoring’s innovative point-of-need testing device addresses the call made by the Government of Canada’s Plan to Mobilize Industry to fight COVID-19. By pivoting and building from our experience in the sensitive area of food and water safety we are now looking forward to working with the Canadian health care community during this unprecedented time.”

With the ability to administer nine tests per hour at the point-of-need in 60 minutes, the SARS-CoV-2 Go-Strips will help contribute to the call from all levels of government to increase testing capacity for COVID-19. 

About Precision Biomonitoring SARS-CoV-2 Go-Strips

Precision Biomonitoring’s easy-to-use Go-Strips are a mobile solution for health care providers in Ontario and across Canada. The device can be transported in a laptop-sized bag, ideal for on the spot tests, especially when results are needed now in emergency rooms and more rural and remote regions.

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

Media Contact:  

Meredith Adams 

416-459-7086 

Madams@national.ca

March 20, 2020

Precision Biomonitoring Announces its Health Canada Submission for Point-of-Care SARS CoV-2 Go-Strips

Precision Biomonitoring Responds to Health Canada’s Call for COVID-19 Research and Development with Innovative Point-of-Care Testing Solution

GUELPH, Ontario and MISSISSAUGA, Ontario, March 20, 2020 – Precision Biomonitoring, an industry leader in developing environmental DNA (eDNA) tools to detect organisms, announces the submission of its point-of-care SARS-CoV-2 Go-Strips and rapid mobile detection device to Health Canada for approval and use in Canada in response to the COVID-19 virus. The submission was based on lab validation data generated  through testing viral samples and its on-going collaboration with major research institutions in Ontario and Manitoba, including with teams that recently identified and isolated the RNA of the new novel coronavirus.

Our recent collaboration with healthcare and research institutions across the country positions us well to work with the Government of Canada and healthcare decision makers to provide innovative, point-of-care testing for COVID-19 in 60 minutes,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “We are looking forward to playing our part in combatting this virus.”

A proud Canadian company, Precision Biomonitoring, recognizes the importance of working with public health officials to ensure the safety of all Canadians. “Our technologies are inspired by our ongoing pursuit for innovation, and in the face of a rapidly evolving situation such as COVID-19, that relentless commitment is all the more critical,” says Thomas. “To know that our company is working towards supporting health care professionals in enabling the diagnosis and care taking place across Canada continues to fuel our efforts. We look forward to a timely response from Health Canada.”

Precision Biomonitoring has a demonstrated track record of being agile and adjusting to the scientific and medical needs of the Canadian landscape. Its ongoing work and strong existing relationships with the Government of Canada, as well as the Canadian Food Inspection Agency in the food safety and animal health space, has provided Precision Biomonitoring with the knowledge and experience necessary to be a trusted, collaborative partner to Health Canada.

About Precision Biomonitoring

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet.

Media Contact: 

Meredith Adams

416-459-7086

madams@national.ca 

July 3, 2019
Precision Biomonitoring and AgriSeq Solutions Announce Strategic Partnership in Genomics

June 18, 2019
Precision Biomonitoring and Birks Natural Heritage Consultants Announce Strategic Partnership Advancing Adoption of Environmental DNA Methods http://bit.ly/2ZxV5cN 

May 14, 2019
Precision Biomonitoring Inc. and EcoMetrix Inc. have joined forces to advance the state of basic and applied science as it relates to Environmental DNA (eDNA) tools, approaches and methodologies. http://bit.ly/2WIHb6w

May 7, 2019
Precision Biomontoring Awarded ‘Build in Canada Innovation Program’ Contract. https://bit.ly/2GkKdaY

https://www.uoguelph.ca/ib/PISCeS

October 11, 2018
Precision Biomonitoring sponsors the first National eDNA National Worshop hosted by University of Guelph on October 11-12,2018

info@precisionbiomonitoring.com
1-226-486-3252

Orchard Park – Suite #226 
5420 Highway 6 North
Guelph ON  Canada
N1H 6J2